Danish Pharmaceutical Society
– The Biopharmaceutical Section
GLP-1: From discovery to versatile drug
Thursday 29st of February, 2024 at 15.00
The peptide hormone GLP-1 was discovered in 1986. Since then, a number of GLP-1-based drugs have been developed and are now used in the treatment of diabetes and obesity. Interestingly, new studies also point toward its potential use in stroke treatment and in reducing smoke cravings.
Program
15.00-15.05: Welcome by the Danish Pharmaceutical Society
Mie Kristensen & Stine Rønholt
Section of Biopharmacy, Danish Pharmaceutical Society
15.05-15.35: Discovery of GLP-1
Jens Juul Holst
(Professor, University of Copenhagen)
15.35-16.05: Turning GLP-1 into a drug compound
Lotte Bjerre Knudsen
(Chief Scientific Advisor, member of EVP leadership team for
Research & Early Development, Novo Nordisk)
16:05-16:30: Coffee and refreshments
16.30-17:00: GLP-1 as a novel approach to stroke treatment
Claus Ziegler Simonsen
(Professor, Aarhus University Hospital)
17:00-17.30: Beyond the scale: Broadening the scope of GLP-1-based therapies
Christoffer Clemmensen
(Associate Professor, University of Copenhagen)
17.30-17.35: Wrap up
Mie Kristensen & Stine Rønholt
Section of Biopharmacy, Danish Pharmaceutical Society
Details
Start:
29. February – 15:00
End:
29. February – 17:35
Website:
https://farmaceutisk-selskab.dk/
Location:
Universitetsparken 2, Auditorium 3
University of Copenhagen
No entry fee, non-members are also welcome
